San Diego company aiming to target glioblastoma with nanotechnology-based approach

Intermediate magnification micrograph of a glioblastoma. HPS stain image courtesy of Wikimedia.

The emerging biopharmaceutical company Global Cancer Technology (GCT; San Diego) is developing a novel x-ray activated therapy to treat glioblastoma, which remains stubbornly difficult to treat.

GCT has a licensing agreement with the University of California, San Diego (UCSD) for a drug delivery platform that unites a nanocrystal to a prodrug that can be activated using radiosurgery. GCT has also acquired two patents for investigational drugs that can cross the blood-brain barrier. One is an inhibitor of phosphatidylinositol 3-kinase (PI3K), a type of enzyme involved in several cellular functions that facilitates rapid growth in glioblastoma. The other compound targets Vps34, a phosphatidylinositol 3-kinase. Both compounds modulate autophagy, a regenerative cellular process. According to UCSD researchers, autophag…

Read more
  • 0